Therapeutic Options for Achieving Realistic Management Goals in your IBS Patients: An Update for Primary Care
GastroenterologyManaging a Patient with Irritable Bowel Syndrome
1.25 ANCC Contact Hours 1.25 AMA PRA Category 1 Credit(s) ™
January 30, 2018
The accreditation for this activity has expired.
Primary Audience:
Primary care clinicians, including physicians, physician assistants, nurse practitioners, nurses and others who diagnose, treat, and manage patients with IBS.
Relevant Terms:
Primary Care
H. Christian Weber, MD
Horst Christian Weber, MD Course Director Department of Medicine, Gastroenterology Boston Medical Center Assistant Professor of Medicine Boston University School of Medicine Boston, MA Associated Chief and Clinical Director, Gastroenterology and Hepatology VA Boston Healthcare System Jamaica Plain, MA
Bio
Dr. Weber joined the faculty of Boston University School of Medicine as Assistant Professor of Medicine in the Section of Gastroenterology in 1997. Dr. Weber is a native of Germany and graduated from Hamburg University Medical School. He completed his training in internal medicine at the University of Mainz, Germany, and at the MetroWest Medical Center in Framingham, MA, and his fellowship in gastroenterology at Georgetown University Medical Center and the National Institutes of Health. He is board-certified in gastroenterology.Albena Halpert, MD
Albena Halpert, MD Consultant Faculty Assistant Professor Section of Gastroenterology Boston University School of Medicine Boston, MA
Bio
| 1. | Identify symptom criteria for the diagnosis of irritable bowel syndrome (IBS) and its subtypes by eliciting a thorough patient history and applying clinical symptom criteria | 2. | Implement available screening and diagnostic tools for the diagnosis of IBS and recognize indications for referral to specialist care |
| 3. | Articulate the range of treatment options (both pharmacologic and non-pharmacologic therapies) for patients with IBS | 4. | Interpret consensus guidelines for the management of IBS |
| 5. | Summarize evidence-based guidelines for effective monitoring of patients with IBS | 6. | Establish strategies to improve communication between patients and healthcare providers concerning their symptoms of IBS and its management in order to improve outcomes |
| 1. | Identify symptom criteria for the diagnosis of irritable bowel syndrome (IBS) and its subtypes by eliciting a thorough patient history and applying clinical symptom criteria |
| 2. | Implement available screening and diagnostic tools for the diagnosis of IBS and recognize indications for referral to specialist care |
| 3. | Articulate the range of treatment options (both pharmacologic and non-pharmacologic therapies) for patients with IBS |
| 4. | Interpret consensus guidelines for the management of IBS |
| 5. | Summarize evidence-based guidelines for effective monitoring of patients with IBS |
| 6. | Establish strategies to improve communication between patients and healthcare providers concerning their symptoms of IBS and its management in order to improve outcomes |
DISCLOSURE POLICY STATEMENT
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Faculty Disclosures
Dr. Christian Weber, Course Director, is a consultant for Allergan and Karos Pharmaceuticals.
Dr. Albena Halpert, Consultant Faculty, is a consultant for Allergan.
Off-Label Discussions
The unlabeled/investigational uses of commercial products will be discussed in this activity.
For IBS-D off-label discussion of probiotics, loperamide, diphenoxylate-atropine, smooth muscle antispasmodics, tricyclic antidepressants, antibiotics and bile salts (cholestyramine) will be included. For IBS-C off-label discussion of fiber supplementation, laxatives, plecanatide (CIC), antispasmodics, SSRI/SNRI and behavioral therapies.
Planning Committee Disclosures
Rachel Bereiweriso, NP, MSN, Nursing Course Advisor for Boston University School of Medicine's Office of Continuing Medical Education, has no financial relationships to disclose.
Michael Burk, Senior Program Manager for Boston University School of Medicine's Office of Continuing Medical Education, has no financial relationships to disclose.
Carmela Townsend, Lead Nurse Planner for Boston University School of Medicine's Office of Continuing Medical Education, has no financial relationships to disclose.
Christopher Drury, consultant medical editor for Boston University School of Medicine's Office of Continuing Medical Education, has no financial relationships to disclose.
Dana Frazier, Program and Grant Manager for Boston University School of Medicine's Office of Continuing Medical Education, has no financial relationships to disclose.
Bret Lashner, MD, Co-Course Director for Boston University School of Medicine's Office of Continuing Medical Education and Professor of Medicine at the Cleveland Clinic, has no financial relationships to disclose.
DISCLAIMER
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
ACCREDITATION STATEMENT
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Contact Hours: 1.25, all of which are eligible for pharmacology credit.
HOW TO RECEIVE CREDIT
In order to successfully complete this activity, you are required to review the entire course content and successfully complete the post-test and evaluation. CME and CNE credit will be awarded provided a score of 70% or better is achieved. A certificate of credit will be available for immediate download to those who successfully complete the examination.
Release Date: 1/31/18
Expiration Date: 1/30/19
Date of Most Recent Review: Not Applicable
Program Code: E.IBS17
For questions about CME, please contact cme@bu.edu or www.bu.edu/cme.
To view Boston University's Privacy Policy, please see http://www.bumc.bu.edu/cme/policies/.
© Trustees of Boston University, 2018
COMMERCIAL SUPPORT
This continuing medical education activity is supported by independent educational grants from Allergan, Ironwood Pharmaceuticals Inc., and Salix Pharmaceuticals Inc.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2024 HealthCourse, Inc. All rights reserved.
